Foundations Investment Advisors LLC Purchases 10,129 Shares of Eli Lilly and Company (NYSE:LLY)

Foundations Investment Advisors LLC raised its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 44.2% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 33,055 shares of the company’s stock after purchasing an additional 10,129 shares during the quarter. Foundations Investment Advisors LLC’s holdings in Eli Lilly and Company were worth $29,285,000 as of its most recent SEC filing.

Several other institutional investors have also recently bought and sold shares of the business. CGN Advisors LLC increased its holdings in Eli Lilly and Company by 1.4% during the 1st quarter. CGN Advisors LLC now owns 1,001 shares of the company’s stock worth $779,000 after purchasing an additional 14 shares in the last quarter. Central Valley Advisors LLC purchased a new position in shares of Eli Lilly and Company during the first quarter valued at approximately $245,000. Annex Advisory Services LLC grew its holdings in Eli Lilly and Company by 14.1% during the first quarter. Annex Advisory Services LLC now owns 4,332 shares of the company’s stock worth $3,370,000 after buying an additional 535 shares in the last quarter. Fermata Advisors LLC raised its position in Eli Lilly and Company by 27.8% in the 1st quarter. Fermata Advisors LLC now owns 1,113 shares of the company’s stock valued at $866,000 after buying an additional 242 shares during the last quarter. Finally, Dynamic Advisor Solutions LLC lifted its stake in Eli Lilly and Company by 2.8% during the 1st quarter. Dynamic Advisor Solutions LLC now owns 15,381 shares of the company’s stock valued at $11,966,000 after acquiring an additional 417 shares in the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have recently commented on LLY. Morgan Stanley reiterated an “overweight” rating and issued a $1,106.00 target price on shares of Eli Lilly and Company in a report on Tuesday, August 27th. Cantor Fitzgerald reissued an “overweight” rating and set a $885.00 target price on shares of Eli Lilly and Company in a research report on Monday, September 16th. Wells Fargo & Company lifted their price target on Eli Lilly and Company from $875.00 to $1,000.00 and gave the stock an “overweight” rating in a report on Friday, August 9th. Guggenheim upped their price objective on Eli Lilly and Company from $884.00 to $1,030.00 and gave the company a “buy” rating in a research note on Friday, August 16th. Finally, Sanford C. Bernstein started coverage on Eli Lilly and Company in a research note on Thursday, October 17th. They set an “outperform” rating and a $1,100.00 target price on the stock. Three analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $1,002.24.

Eli Lilly and Company Stock Performance

NYSE LLY opened at $906.13 on Tuesday. The firm has a market cap of $861.19 billion, a P/E ratio of 133.45, a price-to-earnings-growth ratio of 2.79 and a beta of 0.42. The company has a quick ratio of 0.87, a current ratio of 1.11 and a debt-to-equity ratio of 1.74. The company’s 50 day moving average is $921.65 and its 200-day moving average is $859.57. Eli Lilly and Company has a 12-month low of $547.61 and a 12-month high of $972.53.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Thursday, August 8th. The company reported $3.92 earnings per share for the quarter, beating analysts’ consensus estimates of $2.64 by $1.28. The business had revenue of $11.30 billion during the quarter, compared to analyst estimates of $9.83 billion. Eli Lilly and Company had a net margin of 18.86% and a return on equity of 67.52%. Sell-side analysts predict that Eli Lilly and Company will post 16.49 earnings per share for the current year.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.